1. Home
  2. SXTC vs LUNG Comparison

SXTC vs LUNG Comparison

Compare SXTC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China SXT Pharmaceuticals Inc.

SXTC

China SXT Pharmaceuticals Inc.

HOLD

Current Price

$0.05

Market Cap

92.9M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.88

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTC
LUNG
Founded
2005
1995
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.9M
97.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SXTC
LUNG
Price
$0.05
$1.88
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
★ 25.8M
257.3K
Earning Date
08-19-2019
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.64
EPS
★ N/A
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$0.03
$1.13
52 Week High
$9.59
$2.89

Technical Indicators

Market Signals
Indicator
SXTC
LUNG
Relative Strength Index (RSI) 31.35 50.15
Support Level $0.04 $1.70
Resistance Level $2.59 $2.12
Average True Range (ATR) 0.71 0.11
MACD -0.08 0.01
Stochastic Oscillator 0.02 74.42

Price Performance

Historical Comparison
SXTC
LUNG

About SXTC China SXT Pharmaceuticals Inc.

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: